3 unknown. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Unknown 3 |
| Phase 2 | 1 | Unknown 1 |
Follow Chronic Urticaria: new trials by email Literature Review of Chronic Urticaria trials Research Report on Chronic Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria SYN008, Omalizumab for injection - Chronic Spontaneous Urticaria | Phase 3 | Unknown | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 340 | 2021-07-01 | 2021-06-29 |
| Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous Urticaria Recombinant human interleukin-2 (rhIL-2), Control group - Chronic Spontaneous Urticaria | Phase 2 / Phase 3 | Unknown | Second Xiangya Hospital of Central South University | 56 | 2021-06-16 | 2021-05-20 |
| Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria Omalizimab - Chronic Idiopathic Urticaria | Phase 3 | Unknown | Rabin Medical Center | 20 | 2014-07-01 | 2014-06-18 |
Chronic Disease (3) · Disease Attributes (3) · Hypersensitivity (3) · Hypersensitivity, Immediate (3) · Immune System Diseases (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Skin Diseases (3) · Skin Diseases, Vascular (3) · Skin and Connective Tissue Diseases (3) · Urticaria (3)
Omalizumab (2) · Control Groups (1) · Injections (1) · aldesleukin (1)
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (1) · Rabin Medical Center (1) · Second Xiangya Hospital of Central South University (1)
China (1) · Israel (1)
Michael David, Prof (1) · Qianjin Lu, MD, PhD (1) · Ruo-Yu Li (1)